{"id":50557,"date":"2022-11-07T18:02:16","date_gmt":"2022-11-07T17:02:16","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/edigene-biotechnology-moves-into-new-rd-center-at-waltham-mass-to-advance-proprietary-leaper-technology-into-transformative-in-vivo-rna-editing-therapies\/"},"modified":"2022-11-07T18:02:16","modified_gmt":"2022-11-07T17:02:16","slug":"edigene-biotechnology-moves-into-new-rd-center-at-waltham-mass-to-advance-proprietary-leaper-technology-into-transformative-in-vivo-rna-editing-therapies","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/edigene-biotechnology-moves-into-new-rd-center-at-waltham-mass-to-advance-proprietary-leaper-technology-into-transformative-in-vivo-rna-editing-therapies\/","title":{"rendered":"EdiGene Biotechnology Moves into New R&D Center at Waltham, Mass. to Advance Proprietary LEAPER\u2122 Technology into Transformative in vivo RNA Editing Therapies"},"content":{"rendered":"
\n

BEIJING & WALTHAM, Mass.–(BUSINESS WIRE)–EdiGene, Inc., a global, clinical-stage company focused on translating its gene-editing technologies into transformative genetic medicines for patients with significant unmet medical needs, announced its subsidiary, EdiGene Biotechnology USA, has moved into a new Research & Development Center in Waltham, Mass. to advance proprietary LEAPER\u2122 technology into transformative <\/b>in vivo<\/i> RNA editing therapies with an initial focus on ophthalmology and the central nervous system.\n<\/p>\n

<\/a><\/p>\n

\nLEAPER\u2122 (Leveraging endogenous ADAR for programmable editing of RNA) was developed in a lab at Peking University led by Professor Wensheng Wei, the Scientific Founder of EdiGene, and was first reported in Nature Biotechnology<\/i> in 2019. In February 2022, Professor Wei\u2019s lab published a research article in Nature Biotechnology <\/i>on an upgraded version of LEAPER\u2122 that shows significantly improved efficiency and fidelity of RNA editing in vitro<\/i> and in vivo<\/i>.\n<\/p>\n

\n\u201cMoving into our new R&D Center is a significant milestone for EdiGene. It marks our continued efforts to advance the development of and accelerate the translation of our exciting RNA editing technology at the global level,” said Dong Wei, Ph.D., CEO of EdiGene. \u201cWith a strong foundation in RNA editing and translational expertise, we are committed to developing genetic medicines to address the unmet medical needs for patients around the world.”\n<\/p>\n

\n\u201cWe have been building on our R&D efforts in the greater Boston area with a growing team responsible for drug discovery and development, AAV process development, bioinformatics and clinical development for almost two years,\u201d said Bo Zhang, Ph.D., Head of EdiGene\u2019s U.S. subsidiary. \u201cWe are excited to move into our new site to accommodate our rapidly expanding workforce and laboratory operations. By leveraging our unique platform, our team of talented scientists and professionals are creating innovative therapies through internal R&D efforts and external partnerships.\u201d\n<\/p>\n

\nEarlier this year, EdiGene expanded its management team with the appointment of Syed Mahmood, M.D. as Chief Medical Officer. Dr. Mahmood is a physician-scientist with a proven track record of leadership and experience spanning more than 15 years in all facets of drug development, including translational medicine, clinical development, and medical affairs in the United States in global pharmaceutical and biotechnology companies, including Intensity Therapeutics, Novartis, GlaxoSmithKline, Daiichi Sankyo and GE Healthcare.\n<\/p>\n

\n\u201cI am thrilled to join EdiGene because of the potential of its exciting technology portfolio and the critical development stage of the lead programs,\u201d said Syed Mahmood M.D., Chief Medical Officer of EdiGene. \u201cOur new R&D Center represents a new chapter for EdiGene. It was built not only to meet our current needs, but also to scale with our business as we continue to grow. We are at the cusp of advancing LEAPER\u2122 lead candidates to the clinic in the near future and developing potential therapies for patients with serious unmet needs.\u201d\n<\/p>\n

\nIn terms of LEAPER\u2122-based in vivo<\/i> RNA editing therapeutic development, its proof of concept in multiple in vitro <\/i>and in vivo<\/i> model systems was presented at the RNA Editing Summit and the annual TIDES USA Conference in 2022. EdiGene established a research collaboration with the University of Wisconsin-Madison in November 2021.\n<\/p>\n

\nLocated in the Winter Street office park in the premier suburban Boston office market of Waltham, EdiGene\u2019s 14,000 sq. ft. space holds state-of-the-art laboratories integrated with office space. The opening ceremony hosted representatives from patient advocacy groups, academic and research institutions, industry peers and partners, and investors who share our sense of urgency to meet the medical demand for innovative therapies.\n<\/p>\n

\nAbout EdiGene, Inc.<\/b>\n<\/p>\n

\nEdiGene Inc. is a global, clinical-stage company focused on translating gene-editing technologies into transformative genetic medicines for patients with significant unmet medical needs. Anchored by its proprietary technologies of gene editing, bioinformatics, and high throughput genome-editing screening, EdiGene advances the pipeline on therapeutic platforms of LEAPER\u2122-based in vivo<\/i> RNA base editing, ex vivo<\/i> gene-editing hematopoietic stem cells, <\/i>and ex vivo<\/i> gene-editing T cells for allogeneic CAR-T. Founded in 2015, EdiGene is headquartered in Beijing, with offices in Guangzhou and Shanghai, China, and Waltham, Massachusetts, USA. More information can be found at https:\/\/www.EdiGene.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nXiaomeng Zhang
\n
EdiGene, Inc.
\n
+86 10-80733899
\n
media@edigene.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BEIJING & WALTHAM, Mass.–(BUSINESS WIRE)–EdiGene, Inc., a global, clinical-stage company focused on translating its gene-editing technologies into transformative genetic medicines for patients with significant unmet medical needs, announced its subsidiary, EdiGene Biotechnology USA, has moved into a new Research & Development Center in Waltham, Mass. to advance proprietary LEAPER\u2122 technology into transformative in vivo RNA … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50557","6":"format-standard","7":"category-industry"},"yoast_head":"\nEdiGene Biotechnology Moves into New R&D Center at Waltham, Mass. to Advance Proprietary LEAPER\u2122 Technology into Transformative in vivo RNA Editing Therapies - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/edigene-biotechnology-moves-into-new-rd-center-at-waltham-mass-to-advance-proprietary-leaper-technology-into-transformative-in-vivo-rna-editing-therapies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EdiGene Biotechnology Moves into New R&D Center at Waltham, Mass. to Advance Proprietary LEAPER\u2122 Technology into Transformative in vivo RNA Editing Therapies - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BEIJING & WALTHAM, Mass.–(BUSINESS WIRE)–EdiGene, Inc., a global, clinical-stage company focused on translating its gene-editing technologies into transformative genetic medicines for patients with significant unmet medical needs, announced its subsidiary, EdiGene Biotechnology USA, has moved into a new Research & Development Center in Waltham, Mass. to advance proprietary LEAPER\u2122 technology into transformative in vivo RNA ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/edigene-biotechnology-moves-into-new-rd-center-at-waltham-mass-to-advance-proprietary-leaper-technology-into-transformative-in-vivo-rna-editing-therapies\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-07T17:02:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221107005647\/en\/1627377\/21\/EdiGene_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/edigene-biotechnology-moves-into-new-rd-center-at-waltham-mass-to-advance-proprietary-leaper-technology-into-transformative-in-vivo-rna-editing-therapies\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/edigene-biotechnology-moves-into-new-rd-center-at-waltham-mass-to-advance-proprietary-leaper-technology-into-transformative-in-vivo-rna-editing-therapies\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"EdiGene Biotechnology Moves into New R&D Center at Waltham, Mass. to Advance Proprietary LEAPER\u2122 Technology into Transformative in vivo RNA Editing Therapies\",\"datePublished\":\"2022-11-07T17:02:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/edigene-biotechnology-moves-into-new-rd-center-at-waltham-mass-to-advance-proprietary-leaper-technology-into-transformative-in-vivo-rna-editing-therapies\\\/\"},\"wordCount\":714,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/edigene-biotechnology-moves-into-new-rd-center-at-waltham-mass-to-advance-proprietary-leaper-technology-into-transformative-in-vivo-rna-editing-therapies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221107005647\\\/en\\\/1627377\\\/21\\\/EdiGene_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/edigene-biotechnology-moves-into-new-rd-center-at-waltham-mass-to-advance-proprietary-leaper-technology-into-transformative-in-vivo-rna-editing-therapies\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/edigene-biotechnology-moves-into-new-rd-center-at-waltham-mass-to-advance-proprietary-leaper-technology-into-transformative-in-vivo-rna-editing-therapies\\\/\",\"name\":\"EdiGene Biotechnology Moves into New R&D Center at Waltham, Mass. to Advance Proprietary LEAPER\u2122 Technology into Transformative in vivo RNA Editing Therapies - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/edigene-biotechnology-moves-into-new-rd-center-at-waltham-mass-to-advance-proprietary-leaper-technology-into-transformative-in-vivo-rna-editing-therapies\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/edigene-biotechnology-moves-into-new-rd-center-at-waltham-mass-to-advance-proprietary-leaper-technology-into-transformative-in-vivo-rna-editing-therapies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221107005647\\\/en\\\/1627377\\\/21\\\/EdiGene_logo.jpg\",\"datePublished\":\"2022-11-07T17:02:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/edigene-biotechnology-moves-into-new-rd-center-at-waltham-mass-to-advance-proprietary-leaper-technology-into-transformative-in-vivo-rna-editing-therapies\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/edigene-biotechnology-moves-into-new-rd-center-at-waltham-mass-to-advance-proprietary-leaper-technology-into-transformative-in-vivo-rna-editing-therapies\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/edigene-biotechnology-moves-into-new-rd-center-at-waltham-mass-to-advance-proprietary-leaper-technology-into-transformative-in-vivo-rna-editing-therapies\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221107005647\\\/en\\\/1627377\\\/21\\\/EdiGene_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221107005647\\\/en\\\/1627377\\\/21\\\/EdiGene_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/edigene-biotechnology-moves-into-new-rd-center-at-waltham-mass-to-advance-proprietary-leaper-technology-into-transformative-in-vivo-rna-editing-therapies\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EdiGene Biotechnology Moves into New R&D Center at Waltham, Mass. to Advance Proprietary LEAPER\u2122 Technology into Transformative in vivo RNA Editing Therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EdiGene Biotechnology Moves into New R&D Center at Waltham, Mass. to Advance Proprietary LEAPER\u2122 Technology into Transformative in vivo RNA Editing Therapies - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/edigene-biotechnology-moves-into-new-rd-center-at-waltham-mass-to-advance-proprietary-leaper-technology-into-transformative-in-vivo-rna-editing-therapies\/","og_locale":"en_US","og_type":"article","og_title":"EdiGene Biotechnology Moves into New R&D Center at Waltham, Mass. to Advance Proprietary LEAPER\u2122 Technology into Transformative in vivo RNA Editing Therapies - Pharma Trend","og_description":"BEIJING & WALTHAM, Mass.–(BUSINESS WIRE)–EdiGene, Inc., a global, clinical-stage company focused on translating its gene-editing technologies into transformative genetic medicines for patients with significant unmet medical needs, announced its subsidiary, EdiGene Biotechnology USA, has moved into a new Research & Development Center in Waltham, Mass. to advance proprietary LEAPER\u2122 technology into transformative in vivo RNA ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/edigene-biotechnology-moves-into-new-rd-center-at-waltham-mass-to-advance-proprietary-leaper-technology-into-transformative-in-vivo-rna-editing-therapies\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-07T17:02:16+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221107005647\/en\/1627377\/21\/EdiGene_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/edigene-biotechnology-moves-into-new-rd-center-at-waltham-mass-to-advance-proprietary-leaper-technology-into-transformative-in-vivo-rna-editing-therapies\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/edigene-biotechnology-moves-into-new-rd-center-at-waltham-mass-to-advance-proprietary-leaper-technology-into-transformative-in-vivo-rna-editing-therapies\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"EdiGene Biotechnology Moves into New R&D Center at Waltham, Mass. to Advance Proprietary LEAPER\u2122 Technology into Transformative in vivo RNA Editing Therapies","datePublished":"2022-11-07T17:02:16+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/edigene-biotechnology-moves-into-new-rd-center-at-waltham-mass-to-advance-proprietary-leaper-technology-into-transformative-in-vivo-rna-editing-therapies\/"},"wordCount":714,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/edigene-biotechnology-moves-into-new-rd-center-at-waltham-mass-to-advance-proprietary-leaper-technology-into-transformative-in-vivo-rna-editing-therapies\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221107005647\/en\/1627377\/21\/EdiGene_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/edigene-biotechnology-moves-into-new-rd-center-at-waltham-mass-to-advance-proprietary-leaper-technology-into-transformative-in-vivo-rna-editing-therapies\/","url":"https:\/\/pharma-trend.com\/en\/edigene-biotechnology-moves-into-new-rd-center-at-waltham-mass-to-advance-proprietary-leaper-technology-into-transformative-in-vivo-rna-editing-therapies\/","name":"EdiGene Biotechnology Moves into New R&D Center at Waltham, Mass. to Advance Proprietary LEAPER\u2122 Technology into Transformative in vivo RNA Editing Therapies - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/edigene-biotechnology-moves-into-new-rd-center-at-waltham-mass-to-advance-proprietary-leaper-technology-into-transformative-in-vivo-rna-editing-therapies\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/edigene-biotechnology-moves-into-new-rd-center-at-waltham-mass-to-advance-proprietary-leaper-technology-into-transformative-in-vivo-rna-editing-therapies\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221107005647\/en\/1627377\/21\/EdiGene_logo.jpg","datePublished":"2022-11-07T17:02:16+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/edigene-biotechnology-moves-into-new-rd-center-at-waltham-mass-to-advance-proprietary-leaper-technology-into-transformative-in-vivo-rna-editing-therapies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/edigene-biotechnology-moves-into-new-rd-center-at-waltham-mass-to-advance-proprietary-leaper-technology-into-transformative-in-vivo-rna-editing-therapies\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/edigene-biotechnology-moves-into-new-rd-center-at-waltham-mass-to-advance-proprietary-leaper-technology-into-transformative-in-vivo-rna-editing-therapies\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221107005647\/en\/1627377\/21\/EdiGene_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221107005647\/en\/1627377\/21\/EdiGene_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/edigene-biotechnology-moves-into-new-rd-center-at-waltham-mass-to-advance-proprietary-leaper-technology-into-transformative-in-vivo-rna-editing-therapies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"EdiGene Biotechnology Moves into New R&D Center at Waltham, Mass. to Advance Proprietary LEAPER\u2122 Technology into Transformative in vivo RNA Editing Therapies"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50557","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50557"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50557\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50557"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50557"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50557"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}